DiscoverThe BioCentury ShowEp. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions

Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions

Update: 2024-10-04
Share

Description

CMS’s controversial decision to restrict access to Alzheimer’s mAb treatments, including Aduhelm, approved under FDA’s accelerated pathway was a unique case that is unlikely to set a precedent, former CMS CMO Lee Fleisher told BioCentury. “I do not think this will be repeated,” he said. In an interview with The BioCentury Show's Steve Usdin, Fleisher gives a behind-the-scenes account of the decision-making process, including the role of accelerated approval. He also discusses the opportunities and risks for healthcare posed by AI, and the scientific and legislative steps that will be needed to make real the promise of blood-based multicancer detection technologies.

View full story: https://www.biocentury.com/article/653749

#biotech #biopharma #pharma #lifescience #policy

00:00 - Introduction
01:31 - Behind the Aduhelm Decision
08:01 - Questioning CMS
17:19 - Accelerated Approval
26:34 - AI in Medicine

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions

Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions

BioCentury